SCHEMBL29584553

SCHEMBL29584553

COc1cc(-c2cc(C(=O)N3CC[C@H](C(=O)O)CC34CC4)n[nH]2)c(F)cn1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 1/20 0.40
▸ FFAR1 O14842 9/20 0.35
▸ TBK1 Q9UHD2 3/20 0.34
▸ TLR9 Q9NR96 1/20 0.33
▸ TLR8 Q9NR97 1/20 0.33
▸ TLR7 Q9NYK1 1/20 0.33
▸ CCNT1 O60563 4/20 0.33
▸ CDK9 P50750 4/20 0.33
▸ EGLN1 Q9GZT9 1/20 0.32
▸ FFAR2 O15552 1/20 0.32
▸ CDK1 P06493 1/20 0.32
▸ CDK4 P11802 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ CDK8 P49336 1/20 0.32
▸ CDK7 P50613 1/20 0.32
▸ CDK6 Q00534 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24423491 1.00 FFAR4 (0.40) FFAR4FFAR1TBK1TLR9TLR8
SCHEMBL24423493 1.00 FFAR4 (0.40) FFAR4FFAR1TBK1TLR9TLR8
SCHEMBL29584811 1.00 FFAR4 (0.40) FFAR4FFAR1TBK1TLR9TLR8
SCHEMBL24424096 1.00 FFAR4 (0.40) FFAR4FFAR1TBK1TLR9TLR8
SCHEMBL29584337 1.00 FFAR4 (0.40) FFAR4FFAR1TBK1TLR9TLR8
SCHEMBL24424523 0.92 FFAR4 (0.37) FFAR4FFAR1TBK1TLR9TLR8
SCHEMBL24424524 0.92 FFAR4 (0.37) FFAR4FFAR1TBK1TLR9TLR8
SCHEMBL24424040 0.92 FFAR4 (0.37) FFAR4FFAR1TBK1TLR9TLR8
SCHEMBL25090729 0.92 FFAR4 (0.37) FFAR4FFAR1TBK1TLR9TLR8
SCHEMBL24423911 0.92 FFAR4 (0.37) FFAR4FFAR1TBK1TLR9TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522605-A1 SOLID FORM OF PPAR-GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2025-03-19 — — EP disclosed
CN-119156380-A Solid crystalline forms of PPAR-gamma modulators and methods of use thereof 卫材R&D管理有限公司 2024-12-17 — — CN disclosed
WO-2023219879-A1 SOLID FORM OF PPAR-gamma MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-11-16 — — WO disclosed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 — — EP disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 — — CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 — — US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD FFAR4 25/4885FFAR1 19/4885TBK1 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback